Gilead Sciences, Inc. research snapshot
GILD AI stock analysis reads Gilead Sciences as a cash-generative biopharma company anchored by HIV treatment and prevention, with HIV product sales up 10% in Q1 2026 and a raised 2026 product sales outlook, but with reported earnings guidance now compressed by roughly $9.50 per share of acquired in-process research and development charges and financing costs from the Arcellx, Ouro Medicines, and Tubulis deals. At the August 2, 2026 data cutoff, GILD closed near $130.21 on July 31, 2026, with a verified market value near $161.66 billion. This page uses source-backed data, scenario ranges, technical levels, and a rules-based trading strategy framework. It is informational research, not investment advice.
Current price
$130.21
Market cap
$161.66 billion verified market cap
AI score
68 / 100
Rating
Cash-generative HIV anchor with strong prevention momentum and deal-driven EPS volatility
Trend status
Mixed technical setup just below its 20-day and 200-day trend references
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Gilead sells HIV, liver disease, oncology, and cell therapy medicines with a large recurring HIV base and strong free cash flow conversion. | High |
| Moat | The moat is strongest in HIV, where clinical evidence, prescriber trust, payer access, regulatory approvals, formulation know-how, and prevention scale support durable demand. | Medium-high |
| Management | Management should be judged by HIV lifecycle execution, Yeztugo and lenacapavir uptake, Trodelvy growth, cell therapy stabilization, the integration of Arcellx, Ouro, and Tubulis, dividend coverage, and disciplined capital allocation. | Medium |
| Financial trend | FY2025 revenue rose 2% to $29.443 billion and net income reached $8.510 billion. Q1 2026 revenue rose 4% to $7.0 billion, product sales rose 5% to $6.9 billion, HIV rose 10%, and full-year product sales guidance was raised to $30.0 to $30.4 billion. | High |
| Valuation | At $130.21, audited math shows about 17.7x TTM EPS, 6.9x book value, 15.8x TTM free cash flow, and a dividend yield near 2.5%, with a 29-analyst average price target of $157.15. | Medium-high |
| Technical trend | Financhill scored GILD 47 and rated it Sell, with price below its 8-day, 20-day, and 200-day simple moving averages and above the 50-day SMA, while MACD stayed positive near 0.49. | Medium |
| Risk level | Major risks are HIV pricing and patent pressure, PrEP expansion headwinds, cell therapy competition, oncology trial risk, acquired IPR&D charges, deal financing costs, and regulatory or payer changes. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and product data are detailed. Forecast confidence is medium because drug-specific events and acquisition accounting can reset earnings and multiples. | High data confidence |
| Investment certainty | Investment certainty is medium. GILD has high cash generation, but margin of safety depends on normalized EPS power after 2026 deal charges and on HIV franchise durability. | Medium |
GILD AI stock forecast
The GILD AI stock forecast uses scenario math around the $130.21 cutoff price and normalized EPS near $8.65, the midpoint of the pre-charge 2026 non-GAAP guidance of $8.45 to $8.85 before Gilead reduced guidance by about $9.50 for acquired IPR&D and financing costs. The audited three-year model produced valuation anchors near $191 in the bullish case, $142 in the base case, and $90 in the bearish case before dividends. These are scenario ranges, not guaranteed targets.
$175 to $195
More likely if Biktarvy and Descovy stay resilient, Yeztugo and lenacapavir reach large prevention adoption, Trodelvy and Livdelzi keep growing, anito-cel advances, cell therapy stabilizes, the Arcellx, Ouro, and Tubulis deals add credible pipeline value, and investors pay about 18x normalized earnings.
$135 to $150
More likely if normalized EPS compounds at a low single-digit rate, HIV growth offsets Veklury and HCV declines, oncology improves gradually, and the market values Gilead near a mid-teens earnings multiple.
$80 to $95
More likely if HIV pricing or patent pressure arrives sooner than expected, PrEP expansion stalls, Yeztugo expectations prove too high, cell therapy keeps declining, oncology trials disappoint, or acquired IPR&D spending fails to create durable growth.
GILD AI technical analysis
GILD AI technical analysis is mixed as of the August 2, 2026 cutoff. Financhill listed GILD near $130.21 on its July 30 update, below the 8-day, 20-day, and 200-day simple moving averages but above the 50-day SMA, with a Sell rating and score of 47, an RSI near 48.49, and a MACD near 0.49. StockAnalysis listed the 50-day SMA near $129.74 and the 200-day SMA near $131.77, so live quote confirmation matters before the August 4, 2026 earnings report.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $130.21 | StockAnalysis quote snapshot after the July 31, 2026 close used for market-cap and valuation math. |
| Near support | $127 to $130 | StockAnalysis listed the 50-day SMA near $129.74, with the 20-day SMA near $132.16 and the 8-day SMA near $131.20 on the Financhill snapshot. |
| Secondary support | $120 to $125 | Bollinger Band (100) lower reference sits near $127.58, and RBC Capital listed a $120 price target that is also a psychological and technical support area. |
| Long-term trend reference | $131 to $132 | StockAnalysis listed the 200-day SMA near $131.77 and the 200-day EMA near $129.01, which makes the long-term signal sensitive to source and timestamp. |
| Resistance | $157.29 | StockAnalysis listed the 52-week high near $157.29, which is the major upside reference for a renewed breakout. |
| Momentum | Score 47 / 100, RSI 48.49 | Financhill rated GILD Sell at 47 with RSI near 48.49 and MACD near 0.49, so the signal mix is not clean. |
| Volume | 6.1 million shares in the Financhill snapshot | Volume should be interpreted against the August 4 earnings date, FDA, patent, payer, and deal news because biopharma volume can spike around event risk. |
| Volatility | Event-sensitive large-cap biopharma volatility | Clinical updates, payer decisions, HIV prevention uptake, and acquisition accounting can matter more than normal chart patterns. |
| Invalidation | Close below $127, then below $120 | A break below the $127 to $130 area would weaken the swing setup. A sustained break below the $120 to $125 zone would require a fuller thesis review. |
GILD AI trading strategy
The GILD AI trading strategy below is a rules-based framework for a mature biopharma stock with a large HIV cash engine, dividend support, event risk, and pipeline optionality. It is not personal advice and should be paired with live quotes, filings, FDA calendars, position sizing, and risk controls.
Watch for GILD to reclaim and hold above the $131 to $132 moving-average zone and build toward the $157 52-week high with confirming volume and no negative HIV, payer, trial, or deal news.
A close below $127 should reduce swing confidence. A close below the $120 to $125 support zone should trigger a full review of the technical and fundamental setup.
If GILD pulls back toward the $127 to $130 area without a new patent, pricing, clinical, or guidance problem, compare the reset price with normalized EPS power, free cash flow yield, dividend coverage, and the audited base scenario.
Do not average down through drug-specific bad news. HIV pricing, FDA, trial, and payer events can convert a technical pullback into a fundamental break.
Track Biktarvy, Descovy, Yeztugo, Trodelvy, Livdelzi, Yescarta, Tecartus, Veklury decline, product sales excluding Veklury, operating cash flow, debt repayments, dividend coverage, and the integration of the Arcellx, Ouro, and Tubulis pipeline assets.
Lower confidence if EPS recovery depends mainly on multiple expansion, one-time adjustments, or acquisitions rather than durable product growth and cash generation.
Investment research summary
Gilead converts antiviral and oncology science, clinical evidence, regulatory approvals, payer access, and global commercial execution into recurring medicine revenue for serious diseases.
The moat is deepest in HIV, where product trust, regimen convenience, prevention leadership, reimbursement access, patents, manufacturing quality, and physician familiarity reinforce each other. It narrows when exclusivity weakens or rivals offer better efficacy, safety, dosing, or price.
The thesis fails if HIV growth slows before new products scale, if Yeztugo and lenacapavir adoption falls short of expectations, if oncology and cell therapy assets disappoint, if PrEP expansion hits payer or uptake headwinds, or if acquisition spending and financing costs dilute owner earnings.
Management has protected a large HIV franchise, raised 2026 product sales guidance, repaid debt, paid dividends, and used the Arcellx, Ouro, and Tubulis deals to rebuild the pipeline. The key test is whether these deals produce clinical and commercial returns above their cost.
Biopharma benefits from aging populations, longer chronic disease treatment, HIV prevention innovation, oncology advances, and rare disease demand. The industry also faces patent cliffs, Medicare and payer pressure, clinical binary risk, and policy scrutiny.
GILD is valued below high-growth biotech multiples but not as a distressed stock. Margin of safety depends on whether normalized earnings near the pre-charge 2026 guidance range remain durable after the IPR&D and financing charges are excluded.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| GILD quote reference | $130.21 close on July 31, 2026 | StockAnalysis GILD quote snapshot | August 2, 2026 |
| Market capitalization verification | $161.66 billion, verified as $130.21 x about 1.242 billion shares | Pineify financial_rigor.py and StockAnalysis share data | August 2, 2026 |
| Shares outstanding | 1.24 billion shares outstanding | StockAnalysis GILD statistics | August 2, 2026 |
| TTM financials | $29.74 billion revenue, $9.22 billion net income, $7.35 TTM EPS, and $10.23 billion free cash flow | StockAnalysis GILD statistics | August 2, 2026 |
| Q1 2026 revenue and EPS | $7.0 billion revenue, $6.9 billion product sales, $1.61 GAAP diluted EPS, and $2.03 non-GAAP diluted EPS | Gilead Q1 2026 financial results release | August 2, 2026 |
| Q1 2026 product sales mix | $5.0 billion HIV, $767 million liver disease, $810 million oncology, $407 million cell therapy, and $144 million Veklury | Gilead Q1 2026 financial results release | August 2, 2026 |
| FY2026 guidance | Product sales raised to $30.0 to $30.4 billion, with GAAP EPS guidance of $(3.25) to $(2.85) and non-GAAP EPS guidance of $(1.05) to $(0.65) after about $9.50 of deal-related charges | Gilead Q1 2026 financial results release | August 2, 2026 |
| Q1 2026 cash and marketable debt securities | $8.6 billion per company release, down from $10.6 billion at the end of 2025 after debt repayments and deal-related cash use | Gilead Q1 2026 release and StockAnalysis balance sheet | August 2, 2026 |
| Total debt and net cash position | $22.17 billion total debt and a net cash position of about negative $11.37 billion | StockAnalysis GILD statistics | August 2, 2026 |
| Analyst consensus | Buy, 29 analysts, average price target $157.15, range $120 to $180 | StockAnalysis GILD forecast | August 2, 2026 |
| Technical snapshot | Financhill score 47, price $130.21, RSI 48.49, MACD 0.49, 50-day SMA $129.74, 200-day SMA $131.77 | Financhill GILD technical analysis and StockAnalysis | August 2, 2026 |
This GILD AI stock analysis is an informational research tool only. It is not investment advice, a solicitation, or a personalized recommendation. Forecast ranges are scenarios based on available data as of August 2, 2026 and can be wrong if clinical, regulatory, pricing, competitive, macro, or market multiple assumptions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
